Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome.
Anti-phosphatidylserine/prothrombin antibody
Antiphospholipid syndrome
Obstetric complications
Risk stratification
Thrombosis
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
27
06
2023
revised:
24
09
2023
accepted:
05
10
2023
medline:
6
11
2023
pubmed:
15
10
2023
entrez:
14
10
2023
Statut:
ppublish
Résumé
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the diverse range of aPLs, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have gained significance in clinical practice. The detection of aPS/PT has proven valuable in identifying APS patients and stratifying their risk, especially when combined with other aPL tests like lupus anticoagulant (LA) and anti-β
Identifiants
pubmed: 37838215
pii: S1521-6616(23)00567-3
doi: 10.1016/j.clim.2023.109804
pii:
doi:
Substances chimiques
Prothrombin
9001-26-7
Phosphatidylserines
0
Antibodies, Antiphospholipid
0
beta 2-Glycoprotein I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109804Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no conflict of interest.